Mengya Zhong

896 total citations
36 papers, 572 citations indexed

About

Mengya Zhong is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Mengya Zhong has authored 36 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 9 papers in Pathology and Forensic Medicine and 8 papers in Genetics. Recurrent topics in Mengya Zhong's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Mengya Zhong is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Mengya Zhong collaborates with scholars based in China, United States and Sweden. Mengya Zhong's co-authors include Xuehui Hong, Yubo Xiong, Zhi Gao, Jiabao Zhao, Guohong Zhuang, Xingfeng Qiu, Yongxi Song, Jingsong Ma, Nini Li and Yuhan Ye and has published in prestigious journals such as The EMBO Journal, Blood and Oncogene.

In The Last Decade

Mengya Zhong

32 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mengya Zhong China	14	329	137	118	115	65	36	572
Jiazhang Wei China	14	324 1.0×	194 1.4×	126 1.1×	75 0.7×	94 1.4×	46	606
Jong Won Lee South Korea	18	416 1.3×	147 1.1×	96 0.8×	75 0.7×	67 1.0×	51	680
Pindong Li China	15	340 1.0×	169 1.2×	130 1.1×	77 0.7×	89 1.4×	29	614
Jiayun Hou China	15	301 0.9×	120 0.9×	112 0.9×	79 0.7×	97 1.5×	29	589
U‐Ging Lo United States	18	409 1.2×	192 1.4×	168 1.4×	192 1.7×	93 1.4×	24	770
Guanggai Xia China	12	216 0.7×	153 1.1×	182 1.5×	76 0.7×	91 1.4×	17	534
Beibei Ni China	15	480 1.5×	186 1.4×	133 1.1×	70 0.6×	104 1.6×	33	740
Guanghua Yang China	17	489 1.5×	196 1.4×	155 1.3×	147 1.3×	67 1.0×	69	884
Young Mi Whang South Korea	16	381 1.2×	93 0.7×	153 1.3×	76 0.7×	43 0.7×	35	627

Countries citing papers authored by Mengya Zhong

Since Specialization

Citations

This map shows the geographic impact of Mengya Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengya Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengya Zhong more than expected).

Fields of papers citing papers by Mengya Zhong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengya Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengya Zhong. The network helps show where Mengya Zhong may publish in the future.

Co-authorship network of co-authors of Mengya Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Mengya Zhong. A scholar is included among the top collaborators of Mengya Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengya Zhong. Mengya Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhong, Mengya, et al.. (2025). Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma. Clinical Epigenetics. 17(1). 74–74.

Lai, Qian, Manman Deng, Zhijuan Lin, et al.. (2024). Resensitizing the Imatinib-Resistant Chronic Myeloid Leukemia through Reshaping the Glucose Mtabolism By Insulin Sensitizer. Blood. 144(Supplement 1). 5781–5781.

Lü, Zhen, Qian Lai, Li Z, et al.. (2024). Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia. Current Medical Science. 44(2). 298–308. 3 indexed citations

Zhang, Shuaishuai, Qiang Zhu, Mengya Zhong, et al.. (2023). MSI2 deficiency in ILC3s attenuates DSS-induced colitis by affecting the intestinal microbiota. Frontiers in Immunology. 13. 963379–963379. 8 indexed citations

Zhong, Mengya, et al.. (2023). High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma. International Journal of Toxicology. 42(5). 386–406. 1 indexed citations

Zhong, Mengya, Yating Liu, Yong Zhou, et al.. (2023). Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway. Discover Oncology. 14(1). 118–118. 5 indexed citations

Zhuang, Xinguo, Xun Li, Mengya Zhong, et al.. (2023). Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma. International Journal of Medical Sciences. 21(1). 70–79.

Zhou, Hui, Mengya Zhong, Dongmei Qin, et al.. (2022). Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia. Cancer Letters. 554. 215997–215997. 24 indexed citations

Zhao, Haijun, Mengya Zhong, Yong Zhou, et al.. (2022). Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells. Experimental Hematology and Oncology. 11(1). 29–29. 13 indexed citations

10.

Zhong, Mengya, et al.. (2022). Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway. Blood. 140(Supplement 1). 11578–11578. 1 indexed citations

11.

Zhong, Mengya, et al.. (2022). Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway. Pharmaceuticals. 16(1). 15–15. 8 indexed citations

12.

Ao, Mingtao, Fei Yu, Yixiang Li, et al.. (2021). Carrier-free nanoparticles of camptothecin prodrug for chemo-photothermal therapy: the making, in vitro and in vivo testing. Journal of Nanobiotechnology. 19(1). 350–350. 42 indexed citations

13.

Zhong, Mengya, Yu Liu, Yubo Xiong, et al.. (2021). Application of natural products for inducing ferroptosis in tumor cells. Biotechnology and Applied Biochemistry. 69(1). 190–197. 36 indexed citations

14.

Chen, Yingyu, Guoliang Yan, Yunhan Ma, et al.. (2021). Combination of mesenchymal stem cells and FK506 prolongs heart allograft survival by inhibiting TBK1/IRF3-regulated-IFN-γ production. Immunology Letters. 238. 21–28. 5 indexed citations

15.

Zhong, Mengya, et al.. (2021). Emerging roles of nucleotide metabolism in cancer development: progress and prospect. Aging. 13(9). 13349–13358. 45 indexed citations

16.

Zhong, Mengya, Xingfeng Qiu, Yu Liu, et al.. (2021). TIPE Regulates DcR3 Expression and Function by Activating the PI3K/AKT Signaling Pathway in CRC. Frontiers in Oncology. 10. 623048–623048. 7 indexed citations

17.

Ma, Yunhan, Yingyu Chen, Mengya Zhong, et al.. (2021). Leflunomide Inhibits rat-to-Mouse Cardiac Xenograft Rejection by Suppressing Adaptive Immune Cell Response and NF-κB Signaling Activation. Cell Transplantation. 30. 4211112359–4211112359. 3 indexed citations

18.

Zhong, Mengya, Yubo Xiong, Jiabao Zhao, et al.. (2021). Candida albicans disorder is associated with gastric carcinogenesis. Theranostics. 11(10). 4945–4956. 87 indexed citations

19.

Feng, Xing, Dong Ma, Jiabao Zhao, et al.. (2020). UHMK 1 promotes gastric cancer progression through reprogramming nucleotide metabolism. The EMBO Journal. 39(5). e102541–e102541. 33 indexed citations

20.

Zhong, Mengya, Yu Liu, Lianghai Wang, et al.. (2020). TNFAIP8 promotes the migration of clear cell renal cell carcinoma by regulating the EMT. Journal of Cancer. 11(10). 3061–3071. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact